Milnacipran: An antidepressant with dual selectivity of action on noradrenaline and serotonin uptake

Human Psychopharmacology

Volumn 15, Issue 4, 2000, Pages 255-260

  Delini Stula, A ^a  

^a CNS Medical Research Counselling   (Switzerland)

Author keywords

Adverse events; Antidepressants; Biochemistry; Clinical trials; Depression; Monoamine reuptake inhibition; Pharmacokinetics; Pharmacology

Indexed keywords

CLOMIPRAMINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MILNACIPRAN; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSURIA; HUMAN; NORADRENALIN BRAIN LEVEL; PRIORITY JOURNAL; SEROTONIN BRAIN LEVEL; SIDE EFFECT;

EID: 0034045563     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/1099-1077(200006)15:4<255::AID-HUP165>3.0.CO;2-V     Document Type: Article

References (34)

1. Anderson IM. 1998. SSRIs versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depression Anxiety 7 (Suppl. 1): 11-17.
2. Anderson IM, Tomenson BM. 1994. The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol 8: 238-249.
3. Ansseau M, Von Frenckell R, Mertens C, de Wilde J, Botte L, Devoitille JM, Evrard JL, De Nayer A, Darimont P, Dejaiffe G et al. 1989a. Controlled comparison of two doses of milnacipran (F 2207) and amitriptyline in major depressive inpatients. Psychopharmacology 98: 163-168.
4. Ansseau M, Von Frenckell R, Papart P, Mertens C, De Wilde J, Botte L, Devoitille JM, Evrard JL, De Nayer A, Koch Bourouxhe S, Darimont P, Lecoq A, Mirel J, Couzinier JP, Demarez JP, Serre C. 1989b. Controlled comparison of milnacipran (F2207) 200 mg and amitriptyline in endogenous depressive patients. Human Psychopharmacol 4: 221-227.
5. Ansseau M, Papart P, Troisfontaines B, Bartholomé F, Bataille M, Charles G, Schittecatte M, Darimonl P, Devoitille J-M, De Wilde J, Dufrasne M, Gilson H, Evrard J-L, De Nayer A, Krémer P, Mertens C, Serre C. 1994. Controlled comparison of milnacipran and fluoxetine in major depression. Psychopharmacology 114: 131-137.
6. Assié MB, Le Lann A-D, Stenger A, Briley M. 1990. Repeated administration of milnacipran, a new antidepressant, has no effect on a functional β-adrenergic response in the rat brain. Eur J Pharmacol 183: 741-742.
7. Assié MB, Charveron M, Palmier C, Puozzo C, Moret C, Briley M. 1992. Effects of prolonged administration of milnacipran, a new antidepressant, on receptors and monoamine uptake in the brain of the rat. Neuropharmacology 31: 149-155.
8. Briley M, Prost J-F, Moret C. 1996. Preclinical pharmacology of milnacipran. Int Clin Psychopharmacol 11 (Suppl. 4), 9-14.
9. Carlsson A, Jonason J, Lindqvist M. 1969. On the mechanism of 5-hydroxytryptamine release by thymoleptics. J Pharm Pharmacol 21: 769-773.
10. Clerc G, Pagot R, Bouchard JM, Oules J, Guibert M, Assicot M, Guillard A, Cottin M, Dachary JM, Bezaury JP, Parmentier G, Gresle P, Von Frenckell R, Serre C. 1990. Int́erêt thérapeutique du milnacipran et de la clomipramine au cours d'un traitement de 3 mois: résultats d'un essai comparatif. Psychiat Psychobiol 5: 137-434.
11. DUAG (Danish University Antidepressant Group) 1986. Citalopram: Clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology 90: 131-138.
12. DUAG (Danish University Antidepressant Group) 1990. Paroxetine -a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 18: 289-299.
13. ECNP (European College of Neuropsychopharmacology) 1995. Clinical relevance of response and improvement in psychopharmacology. Eur Neuropsychopharmacol 5: 511-533.
14. Guelfi JD, Ansseau M, Corruble E, Samuelian JC, Tournoux A, Plétan Y. 1998. A double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed patients. Int Clin Psychopharmacol 13: 121-128.
15. Kasper S, Pletan Y, Solles A, Tournoux A. 1996. Comparative studies of milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results. Int Clin Psychopharmacol 11 (Suppl. 4): 35-39.
16. Kerr JS, Sherwood N, Hindmarch I. 1991 The comparative psychopharmacology of 5-HT reuptake inhibitors. Human Psychopharmacol 6: 313-317.
17. Lacroix P, Rocher N, Gandon JM, Panconi E. 1995. Antidepressant effects of milnacipran in the learned helpless test in rats. Eur Neuropsychopharmacol 5 (Suppl. 3): P-2-8.
18. Lecrubier Y, Pletan Y, Solles A, Tournoux A, Magne V. 1996. Clinical efficacy of milnacipran: placebo-controlled trials. Int Clin Psychopharmacol 11 (Suppl. 4): 29-33.
19. Leinonen E, Leopola U, Mehtonen H, Rimon O-P. 1997. Long-term efficacy and safety of milnacipran compared to clomipramine in patients with major depression. Acta Psychiatr Scand 96: 497-504.
20. Lopez-Ibor J, Guelfi JD, Pletan Y, Tournoux A, Prost A. 1996. Milnacipran and selective serotonin reuptake inhibitors in major depression. Int Clin Psychopharmacol 11: 41-46.
21. Macher JP, Sichel JP, Serre C, Von Frenckell R, Huck JC, Demarez JP. 1989. Double-blind placebo-controlled study of milnacipran in hospitalized patients with major depressive disorders. Neuropsychobiology 22: 77-82.
22. Montgomery SA, Prost JF, Solles A, Briley M. 1996. Efficacy and tolerability of milnacipran: an overview. Int Clin Psychopharmacol 11 (Suppl. 4): 47-51.
23. Moret C, Briley M. 1997. Effects of milnacipran and pindolol on extracellular norepinephrine and serotonin levels in the guinea pig hypothalamus. J Neurochem 69: 815-822.
24. Moret C, Charveron M, Finberg JP, Couzinier JP, Briley M. 1985. Biochemical profile of midalcipran (F 2207), 1 - phenyl - 1 - diethyl - aminocarbonyl - 2 - aminomethyl -cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug. Neuropharmacology 24: 1211-1219.
25. Neliat G, Bodinier MC, Panconi E, Briley M. 1996. Lack of effect of repeated administration of milnacipran, a double norepinephrine and serotonin reuptake inhibitor, on the β-adrenoceptor-linked adenylate cyclase system in the rat cerebral cortex. Neuropharmacology 35: 589-593.
26. Palmier C, Puozzo C, Lenehan T, Briley M. 1989. Monoamine uptake inhibition by plasma from healthy volunteers after single oral doses of the antidepressant milnacipran. Eur J Clin Pharmacol 31: 235-238.
27. Puech A, Montgomery SA, Prost JF, Solles A, Briley M. 1997. Milnacipran, a new serotonin and norepinephrine reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol 12: 99-108.
28. Puozzo C, Leonard BE. 1996. Pharmacokinetics of milnacipran in comparison with other antidepressants. Int Clin Psychopharmacol 11 (Suppl. 4): 15-27.
29. Puozzo C, Filaquier C, Briley M. 1985. Plasma levels of F2207, a novel antidepressant, after a single oral administration in volunteers. Brit J Clin Pharmacol 20: 1-29.
30. Puozzo C, Rostin M, Montastruc JL, Houin G. 1987. Absolute bioavailability study of midalcipran (F2207) in volunteers. Proceedings European Congress of Biopharmaceutics and Pharmacokinetics. University of Clermont-Ferrand Press: Clermont-Ferrand; 59-68.
31. Redmond AM, Kelly JP, Leonard BE. 1995. The behavioural effects of milnacipran in the olfactory bulbectomised rat model of depression. Med Sci Res 23: 533-534.
32. Steen A, Den Boer JA. 1997. A double-blind six months comparative study of milnacipran and clomipramine in major depressive disorder. Int Clin Pharmacol 12: 269-281.
33. Stenger A, Couzinier JP, Briley M. 1987. Psychopharmacology of midalcipran, 1-phenyl-1-diethyl-amino-carbonyl-2-aminomethylcyclopropane hydrochloride (F 2207), a new potential antidepressant. Psychopharmacology 91: 147-153.
34. Tignol J, Pujol-Domenech J, Chartres JP, Léger JM, Plétan Y, Tonelli I, Tournoux A, Pezous N. 1998. Double-blind study of the efficacy and safety of milnacipran and imipramine in elderly patients with major depressive episode. Acta Psychiatr Scand 97: 157-165.